A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

Clinical efficacy of oxaliplatin is frequently limited by severe adverse effects and therapy resistance. Acquired insensitivity to oxaliplatin is, at least in part, associated with elevated levels of glutathione (GSH). In this study we report on an oxaliplatin-based platinum(IV) prodrug, which relea...

Descripción completa

Detalles Bibliográficos
Autores principales: Fronik, Philipp, Gutmann, Michael, Vician, Petra, Stojanovic, Mirjana, Kastner, Alexander, Heffeter, Petra, Pirker, Christine, Keppler, Bernhard K., Berger, Walter, Kowol, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814792/
https://www.ncbi.nlm.nih.gov/pubmed/36697790
http://dx.doi.org/10.1038/s42004-022-00661-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814792/
https://www.ncbi.nlm.nih.gov/pubmed/36697790
http://dx.doi.org/10.1038/s42004-022-00661-z

Ejemplares similares